Picture loading failed.

Anti-ITGA4_ITGB7 therapeutic antibody (Pre-made Vedolizumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Vedolizumab, sold under the brand name Entyvio, is a monoclonal antibody medication developed by Millennium Pharmaceuticals, Inc (currently named Takeda Oncology, a subsidiary of Takeda Pharmaceuticals) for the treatment of ulcerative colitis and Crohn's disease. It binds to integrin α4β7 (LPAM-1, lymphocyte Peyer's patch adhesion molecule 1, a dimer of Integrin alpha-4 and Integrin beta-7). Blocking the α4β7 integrin results in gut-selective anti-inflammatory activity. It is marketed under the trade name Entyvio.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-616-1mg 1mg 3090
GMP-Bios-ab-616-10mg 10mg 21890
GMP-Bios-ab-616-100mg 100mg 148000
GMP-Bios-ab-616-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-ITGA4_ITGB7 therapeutic antibody (Pre-made Vedolizumab biosimilar,Whole mAb)
INN Name Vedolizumab
TargetITGA4_ITGB7
FormatWhole mAb
DerivationHumanized
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Approved
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2008
Year Recommended2009
CompaniesMedical College of Wisconsin;Millennium Pharmaceuticals;Takeda;Takeda Oncology
Conditions ApprovedCrohn's disease;Ulcerative colitis
Conditions ActiveGraft-versus-host disease;Coeliac disease
Conditions DiscontinuedMalignant melanoma
Development Techna